The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ALLERGAN PLC SHS G0177J108 3,810 20,000 SH   SOLE   20,000 0 0
AMARIN CORP PLC SPONS ADR NEW 023111206 7,322 450,000 SH   SOLE   450,000 0 0
ANTARES PHARMA INC COM 036642106 840 250,000 SH   SOLE   250,000 0 0
APRICUS BIOSCIENCES INC COM NEW 03832V307 31 100,000 SH   SOLE   100,000 0 0
FLUIDIGM CORP DEL COM 34385P108 3,371 450,000 SH   SOLE   450,000 0 0
GILEAD SCIENCES INC COM 375558103 7,721 100,000 SH   SOLE   100,000 0 0
GLAXOSMITHKLINE PLC SPONSORED ADR 37733W105 4,017 100,000 SH   SOLE   100,000 0 0
LANNET INC COM 516012101 238 50,000 SH Call SOLE   50,000 0 0
NOVELION THERAPEUTICS INC COM NEW 67001K202 2,994 1,011,487 SH   SOLE   1,011,487 0 0
PROSHARES TR ULTSH NASD BIOT 74347B789 2,345 150,000 SH   SOLE   150,000 0 0
TYME TECHNOLOGIES INC COM 90238J103 6,047 2,175,000 SH   SOLE   2,175,000 0 0
VIKING THERAPEUTICS INC COM 92686J106 2,613 150,000 SH   SOLE   150,000 0 0